Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
In Vivo Performance of Oral Liquid Formulations of Budesonide in Healthy Subjects
NCT05429775Phase 1Completed
- Sponsor
- Sandoz
- Start
- Dec 2018
- Primary completion
- Jan 2019
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label trial of EPI-EE in eosinophilic esophagitis (EoE) (4 arms), sponsored by Sandoz. Primary endpoints: Total oesophageal transit time, Time at which 10% radiolabel administered has arrived in the oesophagus and 4 more. Started Dec 2018; status: completed.
02
Drugs
EPI-EE
03
Conditions
eosinophilic esophagitis (EoE)
Beyond the preview
Go deeper on NCT05429775.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05429775.